



Submission No.: KTJS-9259

Session : KST-TST Joint Symposium

Date & Time, Place : November 18 (Sat), 11:00-12:30, Room 3F-1

Session Title : Hot topics in kidney transplantation

Immunosuppression for Renal Transplantation: Implications from the COVID-19 pandemics

Meng-Kun Tsai

National Taiwan University Hospital, Taiwan

Patients with kidney transplantation usually receive combined therapy of immunosuppressive drugs to inhibit immune system and protect their allografts from rejection. During the COVID-19 pandemics, renal transplant recipients were described to have a higher risk of disease progression. We found, in our patients, that a high anti-spike protein antibody titer could be protective against SARS-COVID-2 infection, but a cellular response by interferon-gamma release assay was not. We reported that anti-proliferative agents were negatively associated with both the antibody and cellular responses. Reviewing the literature, implications from the COVID-19 pandemics in the use of immunosuppressive therapy for kidney transplant patients would be presented. Ref. 1. *Front. Immunol.* 13:951576. doi: 10.3389/fimmu.2022.951576. 2. *Transpl Int* 36:11196. doi: 10.3389/ti.2023.11196.